A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells
2024 · Cell · 103 citations
https://doi.org/10.1016/j.cell.2024.01.035
J
Jeremy Bjelajac
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
7
Papers
357
Citations
4
h-index
4
i10-index
Jeremy Bjelajac is an academic researcher. The author has contributed to research in topics: CAR-T cell therapy research & Immune Cell Function and Interaction & T-cell and B-cell Immunology. The author has an h-index of 4, co-authored 6 publications.
ORCID: 0000-0001-7628-1652Papers by this author
worksEngineered CD47 protects T cells for enhanced antitumour immunity
2024 · Nature · 101 citations
https://doi.org/10.1038/s41586-024-07443-8
Skin basal cell carcinomas assemble a pro-tumorigenic spatially organized and self-propagating Trem2+ myeloid niche
2023 · Nature Communications · 27 citations
https://doi.org/10.1038/s41467-023-37993-w
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat